Experimental (Preclinical) Studies and Clinical Trials of Adipose Tissue-Derived Mesenchymal Stem Cells for Autoimmune Diseases

  • Eun Wha Choi
Part of the Stem Cells and Cancer Stem Cells book series (STEM, volume 10)


Mesenchymal stem cells (MSCs) are considered attractive therapeutic tools for the treatment of various diseases, including autoimmune disease. MSCs display many advantageous properties such as immunomodulation, capacity for differentiation and transdifferentiation, homing activity, and paracrine effects. Further, adipose tissue-derived MSCs (ASCs) are regarded an ideal source of these stem cells because of their plentiful supply, availability, non-immunogenic properties, and minimal ethical considerations as well as the fact that their capacity for proliferation and differentiation is less likely to be affected by aging. In the few preclinical studies and clinical trials that have been performed, treatment with ASCs have ameliorated the clinical symptoms of various autoimmune diseases by reducing inflammatory responses, improving Th1/Th2 balance, and inducing regulatory T cells. ASCs are also an ideal vehicle to deliver genes into target tissues for gene therapy because of their unique biological and immunological properties. Using ASCs as a vehicle to insert appropriate therapeutic genes into cells could prove a novel method for immune modulation in autoimmune disease.


Mesenchymal Stem Cell Major Histocompatibility Complex Class Dextran Sulfate Sodium Human ASCs Chronic Experimental Autoimmune Encephalomyelitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Baek SJ, Kang SK, Ra JC (2011) In vitro migration capacity of human adipose tissue-derived mesenchymal stem cells reflects their expression of receptors for chemokines and growth factors. Exp Mol Med 43:596–603PubMedCrossRefGoogle Scholar
  2. Baksh D, Song L, Tuan RS (2004) Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med 8:301–316PubMedCrossRefGoogle Scholar
  3. Blazar BR, Taylor PA, Linsley PS, Vallera DA (1994) In vivo blockade of CD28/CTLA4:B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 83:3815–3825PubMedGoogle Scholar
  4. Chen HT, Lee MJ, Chen CH, Chuang SC, Chang LF, Ho ML, Hung SH, Fu YC, Wang YH, Wang HI, Wang GJ, Kang L, Chang JK (2012) Proliferation and differentiation potential of human adipose-derived mesenchymal stem cells isolated from elderly patients with osteoporotic fractures. J Cell Mol Med 16:582–593PubMedCrossRefGoogle Scholar
  5. Choi EW (2009) Adult Stem Cell Therapy for Autoimmune Disease. Int J Stem Cells 2:122–128Google Scholar
  6. Choi EW (2012) New Therapeutic Challenges in Autoimmune Diseases. In: Chan J (ed) Autoimmune Diseases: Contributing factors, specific cases of autoimmune diseases, and stem cell and other therapies. INTECH, Rijeka, pp 253–280Google Scholar
  7. Choi EW, Shin IS, Lee CW, Youn HY (2008) The effect of gene therapy using CTLA4Ig/silica-nanoparticles on canine experimental autoimmune thyroiditis. J Gene Med 10:795–804PubMedCrossRefGoogle Scholar
  8. Choi EW, Shin IS, Lee HW, Park SY, Park JH, Nam MH, Kim JS, Woo SK, Yoon EJ, Kang SK, Ra JC, Youn HY, Hong SH (2011) Transplantation of CTLA4Ig gene-transduced adipose tissue-derived mesenchymal stem cells reduces inflammatory immune response and improves Th1/Th2 balance in experimental autoimmune thyroiditis. J Gene Med 13:3–16PubMedCrossRefGoogle Scholar
  9. Choi EW, Shin IS, Park SY, Park JH, Kim JS, Yoon EJ, Kang SK, Ra JC, Hong SH (2012) Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum 64:243–253PubMedCrossRefGoogle Scholar
  10. Constantin G, Marconi S, Rossi B, Angiari S, Calderan L, Anghileri E, Gini B, Bach SD, Martinello M, Bifari F, Galiè M, Turano E, Budui S, Sbarbati A, Krampera M, Bonetti B (2009) Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 27:2624–2635PubMedCrossRefGoogle Scholar
  11. Finck BK, Linsley PS, Wofsy D (1994) Treatment of murine lupus with CTLA4Ig. Science 265:1225–1227PubMedCrossRefGoogle Scholar
  12. Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182–205PubMedCrossRefGoogle Scholar
  13. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM (1993) Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci U S A 90:6586–6590PubMedCrossRefGoogle Scholar
  14. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M (2009) Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 60:1006–1019PubMedCrossRefGoogle Scholar
  15. Gonzalez-Rey E, Anderson P, González MA, Rico L, Büscher D, Delgado M (2009) Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 58:929–939PubMedCrossRefGoogle Scholar
  16. Jantunen E, Myllykangas-Luosujärvi R (2000) Stem cell transplantation for treatment of severe autoimmune diseases: current status and future perspectives. Bone Marrow Transplant 25:351–356PubMedCrossRefGoogle Scholar
  17. Kuby J (1994) Autoimmunity. In: Kuby J (ed) Immunology, 2nd edn. W. H. Freeman and Company, New York, pp 445–467Google Scholar
  18. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:263–274PubMedCrossRefGoogle Scholar
  19. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, Linsley PS, Bluestone JA (1992) Longterm survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 257:789–792PubMedCrossRefGoogle Scholar
  20. Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, Singh C, Tepper MA (1992) Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257:792–795PubMedCrossRefGoogle Scholar
  21. Matsumoto I, Staub A, Benoist C, Mathis D (1999) Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286:1732–1735PubMedCrossRefGoogle Scholar
  22. McGinley L, McMahon J, Strappe P, Barry F, Murphy M, O’Toole D, O’Brien T (2011) Lentiviral vector mediated modification of mesenchymal stem cells & enhanced survival in an in vitro model of ischaemia. Stem Cell Res Ther 2:12PubMedCrossRefGoogle Scholar
  23. Meirelles Lda S, Fontes AM, Covas DT, Caplan AI (2009) Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 20:419–427PubMedCrossRefGoogle Scholar
  24. Naldini L (1998) Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr Opin Biotechnol 9:457–463PubMedCrossRefGoogle Scholar
  25. Park J, Ries J, Gelse K, Kloss F, von der Mark K, Wiltfang J, Neukam FW, Schneider H (2003) Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Gene Ther 10:1089–1098PubMedCrossRefGoogle Scholar
  26. Ponte AL, Marais E, Gallay N, Langonné A, Delorme B, Hérault O, Charbord P, Domenech J (2007) The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 25:1737–1745PubMedCrossRefGoogle Scholar
  27. Ra JC, Kang SK, Shin IS, Park HG, Joo SA, Kim JG, Kang BC, Lee YS, Nakama K, Piao M, Sohl B, Kurtz A (2011) Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med 9:181PubMedGoogle Scholar
  28. Siatskas C, Chan J, Field J, Murphy K, Nasa Z, Toh BH, Alderuccio F (2006) Gene therapy strategies towards immune tolerance to treat the autoimmune diseases. Curr Gene Ther 6:45–58PubMedCrossRefGoogle Scholar
  29. Taneja V, David CS (2001) Lessons from animal models for human autoimmune diseases. Nat Immunol 2:781–784PubMedCrossRefGoogle Scholar
  30. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA (1996) Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U S A 93:8563–8568PubMedCrossRefGoogle Scholar
  31. Wang J, Liao L, Tan J (2011) Mesenchymal-stem-cell-based experimental and clinical trials: current status and open questions. Expert Opin Biol Ther 11:893–909PubMedCrossRefGoogle Scholar
  32. Wen L, Chen NY, Tang J, Sherwin R, Wong FS (2001) The regulatory role of DR4 in a spontaneous diabetes DQ8 transgenic model. J Clin Invest 107:871–880PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Laboratory Animal Research CenterSamsung Biomedical Research InstituteSeoulRepublic of Korea
  2. 2.School of MedicineSungkyunkwan UniversitySeoulRepublic of Korea

Personalised recommendations